Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 233Neoplasms 163Prostatic Neoplasms 143Colorectal Neoplasms 105Lung Neoplasms 97Leukemia, Myeloid, Acute 74Pancreatic Neoplasms 72Carcinoma, Non-Small-Cell Lung 71Multiple Myeloma 61Brain Neoplasms 58Precursor Cell Lymphoblastic Leukemia-Lymphoma 51Melanoma 51Glioblastoma 48Carcinoma, Hepatocellular 45Ovarian Neoplasms 44Head and Neck Neoplasms 43Uterine Cervical Neoplasms 41Neoplasm Metastasis 41Sarcoma 40Glioma 39Stomach Neoplasms 37Hematologic Neoplasms 37Squamous Cell Carcinoma of Head and Neck 35Recurrence 35Lymphoma, Non-Hodgkin 34Carcinoma, Renal Cell 34Esophageal Neoplasms 33Lymphoma 32Leukemia 32Rectal Neoplasms 31

Interventions

dalpiciclib 1N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × HR+/HER2- Advanced Breast Cancer × 30 days × Clear all
NCT05586841 2026-05-29

Exploration of Dalpiciclib + Chidamide in HR+/HER2- Advanced Breast Cancer After Failure of CDK4/6 Inhibitor: a Phase â… b Study

Beijing 302 Hospital

Phase 1 Completed
22 enrolled
Breast

HR+/HER2- Advanced Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡